AIDS activists have reported that public health facilities in South Africa's Free State Province are experiencing serious shortages of condoms, with some clinics reporting complete stockouts. The Treatment Action Campaign (TAC), an AIDS lobby group, contacted 41 clinics in the province: four reported shortages of condoms and eleven said they had none at all. One clinic in the provincial capital, Bloemfontein, said the depot that normally supplied them with condoms had run out. Free State attracted controversy in November 2008 after the provincial health budget had been overspent to such an extent that the authorities stopped initiating HIV-positive patients on antiretroviral treatment. The national department of health blamed a countrywide shortage in December 2008 on a delay in awarding a new tender. TAC speculated that the delay might still be affecting supply, as it used to receive about one million condoms a month from the health department for distribution, but could now only get hold of about half that quantity.
Equity and HIV/AIDS
In this study, the main objective was to estimate the impact of global strategies, such as pooled procurement arrangements, third-party price negotiation and differential pricing, on reducing the price of antiretrovirals (ARVs). Researchers estimated the impact of global strategies to reduce ARV prices using data on 7,253 procurement transactions from July 2002 to October 2007. They found that large purchase volumes did not necessarily result in lower ARV prices. Although current plans for pooled procurement will further increase purchase volumes, savings are uncertain and should be balanced against programmatic costs. Third-party negotiations by the Clinton HIV/AIDS Initiative resulted in lower generic ARV prices. Generics were less expensive than differentially priced branded ARVs, except where little generic competition exists. Alternative strategies for reducing ARV prices, such as streamlining financial management systems, improving demand forecasting and removing barriers to generics, should be explored.
This study set out to determine the incidence of HIV during pregnancy as defined by seroconversion using a repeat HIV rapid testing strategy during late pregnancy. It adopted a cross-sectional design within a prevention of mother-to-child transmission programme. Pregnant women were retested between 36 and 40 weeks of gestation, provided that they had been tested HIV negative at least three months prior. Single women were at 2.5 times higher risk of seroconverting during pregnancy. In general, HIV incidence during pregnancy was four times higher than in the non-pregnant population. Public health programmes need to continue to reinforce prevention strategies and HIV retesting during pregnancy. The latter also offers an additional opportunity to prevent mother-to-child transmission and further horizontal transmission. Further research is required to understand the cause of primary HIV infection in pregnancy.
Little is known about the stage at which those infected with HIV present for treatment in sub-Saharan Africa. This study conducted a cross-sectional analysis of initial visits to the Immune Suppression Syndrome Clinic of the Mbarara University Teaching Hospital, Uganda, totalling 2,311 patients with an initial visit between February 2007 and February 2008. The median age of the patients was 33 years and 64% were female. More than one third (40%) were categorised as late presenters (stage three or four, according to the World Health Organization disease levels). Late presentation was associated with a lower education level, unemployment, living in a household with others or being unmarried, whereas being pregnant, having young children and consuming alcohol in the prior year were associated with early presentation. Targeted public health interventions to facilitate earlier entry into HIV care are needed, as well as additional study to determine whether late presentation is due to delays in testing vs. delays in accessing care.
Health experts and scientists have accused the world's wealthiest countries of abandoning the goal of universal access to HIV prevention, care and treatment by 2010. ‘We must hold the G8 leaders accountable for their failure to deliver on their promises,’ said Julio Montaner, president of the International Aids Society (IAS), on opening the Fifth IAS Conference on Pathogenesis, Diagnosis and Treatment in Cape Town on 19 July. Montaner, who is also director of the British Columbia Centre for Excellence in HIV/AIDS, was sharply critical of the world's most powerful industrialised countries, who in 2005 committed to developing a comprehensive response to the AIDS pandemic that would achieve universal access to treatment by next year, yet have failed to renew these promises at the G8 summit held from 8–10 July. ‘HIV/AIDS was indeed the elephant in the room,’ he said. ‘In 2009, the eight most powerful economies in the world left HIV off their priority agenda.’
Pharmaceutical giant GlaxoSmithKline has announced plans to invest up to US$97 million over 10 years in improving antiretroviral (ARV) treatment for children and adults in sub-Saharan Africa. The world's second largest drug manufacturer has already pledged US$16 million in seed funding to a public-private partnership that will develop new paediatric formulations of ARV drugs. Less than 10 percent of patients on ARVs in Africa are children and, although thirteen ARV formulations specifically for children are available, they are not adapted for use in resource-poor settings. Most are in liquid form, and come as three, often unpalatable, separate drugs that children find difficult to take. The company has also launched a new ‘Positive Action for Children’ fund of US$80 million over 10 years to help prevent mother-to-child transmission of HIV, and to support orphans and vulnerable children. It made the announcement after activists and governments put pressure on drug companies to do more to make life-saving medicines available in developing countries.
This study’s main aim was to determine what US$577 million in funding from the US President’s Fund for AIDS Relief (PEPFAR) between 2004 and 2008 has achieved in Zambia. Its findings are based on interviews with HIV and AIDS organisations, activists, medical professionals, community leaders, policymakers and programme participants. PEPFAR followed the ABC (abstain, be faithful and use a condom) approach to HIV prevention in Zambia but, according to this report, in 2008, US$20.5 million was channelled to programmes focused on abstinence and being faithful, compared to only US$12.4 million allocated to programmes promoting other approaches, including the use of condoms. Only four organisations received funding to promote condom use. ‘The disproportionate emphasis on abstinence-until-marriage [...] has created a distinctly anti-condom atmosphere,’ the authors noted. They recommended more extensive sex education programmes.
Widespread early therapy for HIV is intellectually compelling because it targets viral load, the major biological risk factor for transmission and disease progression. Delaying treatment until HIV has inflicted severe damage on the immune system and further transmission occurs is a different practice to the approach of other infectious diseases such as tuberculosis. Earlier diagnosis and treatment offer opportunity for ‘positive prevention’, emphasising other health interventions, as well as enhancing the sexual and reproductive health and rights of persons living with HIV. Papers published in 2008 suggested anti-retroviral therapy (ART) may be considered a means of limiting HIV spread, as it reduces viral load. One paper reported that annual universal voluntary HIV testing followed by immediate ART could reduce HIV incidence by about 95% within a decade, with cost-saving over the medium term. Nonetheless, the world requires stronger evidence before policy development on ART for HIV prevention can be envisaged.
The objective of this study was to gain a greater understanding of published safety data for candidate vaginal microbicides. It systematically reviewed twenty-one human safety trials in peer-reviewed journals, involving the use of 11 vaginal microbicides by a total of 1,465 women. There were few findings of significant difference between women in active and control arms of trials. Confidence intervals in the analyses were generally very wide, and most studies were unable to exclude differences of a substantial magnitude between treated and control women. Larger and longer safety studies are necessary to detect clinically important toxicities, including those that indicate a potential increase in HIV risk, before they are ready for large-scale effectiveness trials and use in the public sector.
It is becoming clear that HIV/AIDS spreads most rapidly among poor, marginalised, women, colonised and disempowered groups of people more than others. The HIV/AIDS epidemic is exacerbated by the social, economic, political, and cultural conditions of societies such as gender, racial, class, and other forms of inequalities. Sub-Saharan African countries are severely hit by HIV/AIDS. For these countries the pandemic of HIV/AIDS requires them to go the extra mile in their efforts. The objective of this paper is to promote the need to go beyond the biomedical model of ‘technical fixes’ and the traditional public health education tools, and come up with innovative ideas and strategic thinking to contain the epidemic. It argues that containing the HIV/AIDS epidemic and improving family and community health requires giving appropriate attention to the social illnesses that are responsible for exacerbating biological disorders.